Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| IAM | 3 | neutral | 2/10 | Form 3 initial beneficial ownership filing for Michael Secora, newly appointed CFO & Chief Corporate Development Officer | Oct 14, 2026 |
| IAM | 3 | neutral | 2/10 | Form 3 initial beneficial ownership filing for Neil Josephson, newly appointed Chief Medical Officer of Iambic Therapeut | Oct 14, 2026 |
| LKFT | 6-K | neutral | 4/10 | Lakefront Biotherapeutics completed the sale of its preclinical CAR-T pipeline to Armed Cell Therapeutics for an $8 mill | Oct 14, 2026 |
| SKYE | SC 13G | neutral | 4/10 | Tang Capital Management, LLC and affiliated entities (Kevin Tang) filed a Schedule 13G disclosing a 6.0% passive stake i | Oct 14, 2026 |
| ELAN | INST-CLUSTER | bullish | 4/10 | Three asset managers increased their Elanco Animal Health positions in Q3 2026, led by Artemis Investment Management add | Oct 14, 2026 |
| JSPR | S-3 | bearish | 7/10 | Jasper Therapeutics filed an S-3 shelf registration to register up to 284,013,011 shares of common stock for resale by s | Oct 14, 2026 |
| VSTM | 8-K | bearish | 6/10 | Verastem priced a public offering of 30,937,500 shares of common stock at $8.00/share and pre-funded warrants to purchas | Oct 14, 2026 |
| IBRX | 8-K | bullish | 7/10 | ImmunityBio announced FDA approval expanding ANKTIVA's indication to include BCG-unresponsive NMIBC patients with papill | Oct 14, 2026 |
| MTEX | 8-K | bullish | 5/10 | Mannatech filed an 8-K reporting it has entered into a share purchase agreement to acquire 100% direct ownership of Mann | Oct 14, 2026 |
| VSTM | 424B5 | bearish | 6/10 | Verastem priced a $250M underwritten public offering of 30,937,500 common shares at $8.00/share (a ~7.4% premium to the | Oct 14, 2026 |
| RLYB | S-4/A | neutral | 6/10 | Rallybio filed Amendment No. 4 to its S-4 registration statement for the proposed reverse merger with Avenzo Therapeutic | Oct 14, 2026 |
| WVE | DEF 14A | neutral | 4/10 | Wave Life Sciences filed its definitive proxy statement for the 2026 Annual Meeting on November 12, 2026. Key proposals | Oct 14, 2026 |
| CAPR | SC 13G/A | bearish | 5/10 | Millennium Management LLC filed an amended Schedule 13G disclosing a passive stake of 2.9% (1,669,083 shares) in Caprico | Oct 14, 2026 |
| VSTM | 424B5 | bearish | 6/10 | Verastem is conducting a dilutive underwritten public offering of common stock and pre-funded warrants, with pricing and | Oct 14, 2026 |
| RZLT | 8-K | neutral | 5/10 | Rezolute announced completion of enrollment in its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism, with top | Oct 14, 2026 |
| ASND | 6-K | neutral | 2/10 | Ascendis Pharma filed its updated Articles of Association on Form 6-K, reflecting the grant of 35,890 warrants to employ | Oct 14, 2026 |
| EVO | SC 13D/A | bearish | 7/10 | Mubadala Investment Company PJSC and its affiliates have completely divested their entire stake in Evotec SE, selling 11 | Oct 14, 2026 |
| ELVN | 8-K | neutral | 3/10 | Enliven Therapeutics appointed Kristine Ball to its Board of Directors, effective October 14, 2026, and disclosed plans | Oct 14, 2026 |
| IRLA | SC 13G | neutral | 4/10 | Foresite Capital Fund VI LP and affiliated entities disclosed a 6.0% beneficial ownership stake in IRulya Therapeutics I | Oct 14, 2026 |
| SILO | 8-K | neutral | 3/10 | Silo Pharma acquired software and IP assets marketed as 'Reputation Endpoints' from Larry King in exchange for 150,000 r | Oct 14, 2026 |
| CHRS | PRESS-RELEASE | neutral | 4/10 | Coherus Oncology announced it will release interim clinical data for tagmokitug (anti-CCR8 antibody) combined with torip | Oct 14, 2026 |
| LSTA | 8-K | neutral | 2/10 | Lisata Therapeutics appointed Jeffrey Farrow to its Board of Directors, filling a newly created seat (expanding the boar | Oct 14, 2026 |
| PDSB | S-3 | bearish | 7/10 | PDS Biotech filed an S-3 shelf registration to register up to 110,001,540 shares of common stock for resale by selling s | Oct 14, 2026 |
| CRSP | 144 | neutral | 2/10 | Director George Simeon filed a Form 144 notice to sell 14,514 shares of CRISPR Therapeutics common stock, with an estima | Oct 14, 2026 |
| NRIX | 144 | neutral | 2/10 | Director Julia P. Gregory filed a Form 144 notice of intent to sell 22,583 shares of Nurix Therapeutics common stock, wi | Oct 14, 2026 |
| RTSN | SC 13D | neutral | 3/10 | CEO and co-founder Eric Keller filed a Schedule 13D disclosing beneficial ownership of 598,598 shares (7.07% of outstand | Oct 14, 2026 |
| ENTX | DEF 14A | mixed | 6/10 | Entera Bio is holding a special shareholder meeting on November 24, 2026, to vote on eight proposals tied to its $275 mi | Oct 14, 2026 |
| CRVO | 8-K | neutral | 2/10 | CervoMed Inc. filed an 8-K under Item 7.01 to disclose that an investor presentation containing information about its bu | Oct 14, 2026 |
| XTLB | 6-K | neutral | 2/10 | XTL Biopharmaceuticals filed a 6-K reporting the resignation of external director Iris Shapira Yalon for personal reason | Oct 14, 2026 |
| REGN | 144 | neutral | 3/10 | Andrew J. Murphy, an officer of Regeneron Pharmaceuticals, filed a Form 144 notice of intent to sell 4,147 shares of com | Oct 14, 2026 |